Welcome

World Pharma News is an ambitious online news service dedicated to the world pharmaceutical industry. Our main goal is to keep our readers informed about the latest worldwide pharmaceutical news, realizations and achievements.

Register now to be in touch with our last developments and achievements or Subscribe to World Pharma News alerts by Email (a free service delivered by FeedBurner).

Non progredi est regredi.

World Pharma News .net Explore the first worldwide Web 2.0 pharmaceutical news portal and 'Vote', 'Comment' or 'Submit' pharmaceutical news articles or other pharmaceutical web resources!
For further information, please visit http://www.worldpharmanews.net
Google Groups
Get all news digests delivered to your inbox, subscribe to World Pharma News Google Group.
Email:

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]

Pharmaceutical RSS News

Start your day with worldwide pharmaceutical RSS news
[ Amgen | AstraZeneca | Boehringer Ingelheim | Bristol-Myers Squibb | GlaxoSmithKline | Janssen-Cilag | Johnson & Johnson | Novartis | Novo Nordisk | Pfizer | Roche | Shire | Takeda ]
European Commission European Commission - Pharmaceuticals
FDA US Food and Drug Administration

Sponsored Ads

Google

Sponsored Ads

 

World Pharma News .net / Published News

Our RSS News Channels

Sponsored Ads

Breaking World Pharma News
Pfizer Reports Second-Quarter 2008 Results
Thursday, 24 July 2008
Pfizer IncPfizer Inc (NYSE: PFE) reported financial results for the second-quarter 2008. The Company recorded revenues of $12.1 billion, an increase of 9% compared with $11.1 billion in the year-ago quarter. In the U.S., revenues were $4.8 billion, a decrease of 2%, while international revenues were $7.4 billion, an increase of 18%. Revenues reflect the positive impact of foreign exchange, which increased revenues by approximately $800 million or 7%, as well as the solid performance of many key products.
Read more...
 
First call for Innovative Medicines Initiative a success
Wednesday, 23 July 2008
The first stage of calls for the Innovative Medicines Initiative (IMI), which is supported by the EU with €1 billion in funding, was recently closed and is already being regarded as a success by many of those involved. From 30 April until 15 July 2008, numerous consortia of academia, small and medium-sized enterprises (SMEs), regulatory organisations and industries not affiliated with the European Federation of Pharmaceutical Industries and Associations (EFPIA) submitted their Expressions of Interest to the IMI Joint Undertaking (IMI JU) first Call for proposals.
Read more...
 
Cellular Imaging & Analysis 2008 Event by European Pharmaceutical Review
Tuesday, 22 July 2008
19-20 November, 2008, Basel, Switzerland.
Cellular Imaging and Analysis is becoming one of the hottest topics in the field of pharmaceutical research and development. Technical or diagnostic progress made almost hourly, this multi-disciplinary set of challenges and opportunities is proving one of the most profoundly effective in the history of science.
Read more...
 
GlaxoSmithKline teams up with academia to develop new medicines of value
Tuesday, 22 July 2008
GlaxoSmithKline (GSK)GlaxoSmithKline (GSK) is launching a ground-breaking new concept which will tap into the highest quality thinking in academia to optimise the early clinical development of new GSK medicines in a model of shared risk and reward.
Read more...
 
New FP7 eHealth Project - preDiCT
Monday, 21 July 2008
The preDiCT project officially launched 1 June 2008, with a mission to model, simulate, and ultimately predict the impact of pharmacological compounds on the heart's rhythm using computer models. This will require advances beyond the current state-of-the-art in:
  • Mathematical models of individual ion channels, which control how and when cells contract;
  • Tissue models, which encapsulate chemical processes and physical relationships at millions of separate points in the heart; and
Read more...
 
Novartis gains momentum with strong performance in first half of 2008
Saturday, 19 July 2008
Novartis AG
  • First-half results for continuing operations led by improving Pharmaceuticals performance ahead of expectations and expansion in Vaccines and Diagnostics
  • Net sales rise 11% (+2% in local currencies) to USD 20.6 billion
  • Operating income advances 12% to USD 4.9 billion on business expansion, productivity gains and currency benefits
Read more...
 
Sales Force Effectiveness Russia-CIS
Friday, 18 July 2008
eyeforpharma7-8 October, 2008, Moscow, Russia
These two intensive days address the most important aspects of SFE in Russia and CIS region. Following on from years of highly successful Global Pharmaceutical Sales conferences eyeforpharma's latest offering in this field guarantees the insights, strategies and contacts to drive sales growth and measure ROI in complex and changing environment.
Read more...
 
Abbott Reports Stronger-than-Expected Sales and Earnings Growth in Second Quarter
Thursday, 17 July 2008
AbbottAbbott (NYSE: ABT) announced financial results for the second quarter ended June 30, 2008.
  • Diluted earnings per share, excluding specified items, were $0.84, above Abbott's previously announced guidance range of $0.78 to $0.80, reflecting 21.7 percent growth. Diluted earnings per share under Generally Accepted Accounting Principles (GAAP) were $0.85, up 34.9 percent.
Read more...
 
Boehringer Ingelheim FENS Award for exceptional research in neuroscience
Wednesday, 16 July 2008
Boehringer IngelheimThe 2008 Boehringer Ingelheim FENS Research Award goes to Pascal Fries, MD, PhD, from the F.C. Donders Centre for Cognitive Neuroimaging in Nijmegen, The Netherlands. At the Congress of the Federation of European Neuroscience Societies (FENS) taking place from 12-16 July 2008 in Geneva, on the occasion of a special lecture by the prize winner, the Boehringer Ingelheim FENS Research Award will be presented for the fourth time.
Read more...
 
BASF and Transinsight agree to collaborate in exploring alternatives to animal testing
Tuesday, 15 July 2008
BASF SE and Transinsight GmbH, a provider of semantic search technologies for Web 2.0, have agreed to establish close cooperation in the area of semantic analyses to search for alternatives to animal testing. Together with the German Federal Institute for Risk Assessment (Bundesinstitut für Risikobewertung BfR), both companies will expand the first specialized semantic search engine for this research area called www.Go3R.org to become a global internet platform.
Read more...